At Bancorp buys $8.2 Million stake in St. Jude Medical (STJ)

St. Jude Medical (STJ) : At Bancorp scooped up 23,463 additional shares in St. Jude Medical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 108,654 shares of St. Jude Medical which is valued at $8.2 Million.St. Jude Medical makes up approximately 1.26% of At Bancorp’s portfolio.

Other Hedge Funds, Including , Nomura Asset Management Co Ltd boosted its stake in STJ in the latest quarter, The investment management firm added 760 additional shares and now holds a total of 33,102 shares of St. Jude Medical which is valued at $2.5 Million. St. Jude Medical makes up approx 0.05% of Nomura Asset Management Co Ltd’s portfolio.Champlain Investment Partners boosted its stake in STJ in the latest quarter, The investment management firm added 164,030 additional shares and now holds a total of 1,378,345 shares of St. Jude Medical which is valued at $104.4 Million. St. Jude Medical makes up approx 1.89% of Champlain Investment Partners’s portfolio.Thompson Davis boosted its stake in STJ in the latest quarter, The investment management firm added 86 additional shares and now holds a total of 274 shares of St. Jude Medical which is valued at $20,577. St. Jude Medical makes up approx 0.03% of Thompson Davis’s portfolio.

St. Jude Medical opened for trading at $77.04 and hit $77.625 on the upside on Wednesday, eventually ending the session at $77.44, with a gain of 0.56% or 0.43 points. The heightened volatility saw the trading volume jump to 32,82,018 shares. Company has a market cap of $22,014 M.

On the company’s financial health, St. Jude Medical reported $0.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.88. The company had revenue of $1448.00 million for the quarter, compared to analysts expectations of $1437.78 million. The company’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.93 EPS.

Investors should note that on May 4, 2016, St. Jude Medical announced a cash dividend of $0.3100. The company’s management has announced Jun 28, 2016 as the ex-dividend date and fixed the record date on Jun 30, 2016. The payable date has been fixed on Jul 29, 2016.

Many Wall Street Analysts have commented on St. Jude Medical. St. Jude Medical was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on May 10, 2016. St. Jude Medical was Downgraded by Credit Suisse to ” Neutral” on May 3, 2016. St. Jude Medical was Downgraded by Morgan Stanley to ” Equal-Weight” on May 2, 2016.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.